Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Phase 1 Completed
40 enrolled
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Phase 1 Completed
86 enrolled 17 charts
A Trial Evaluating TG4050 in Ovarian Carcinoma.
Phase 1 Completed
64 enrolled 14 charts
Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer
Phase 1 Completed
15 enrolled
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Phase 1 Completed
136 enrolled
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
Phase 1 Completed
26 enrolled
CAR T Cells in Mesothelin Expressing Cancers
Phase 1 Completed
65 enrolled 14 charts
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Phase 1 Completed
9 enrolled
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 1 Completed
25 enrolled
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer
Phase 1 Completed
27 enrolled 21 charts
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer
Phase 1 Completed
18 enrolled
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Phase 1 Completed
32 enrolled 37 charts
Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 1 Completed
24 enrolled
INTRO
Phase 1 Completed
11 enrolled
POPOPO
Phase 1 Completed
12 enrolled
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
Phase 1 Completed
44 enrolled
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Phase 1 Completed
132 enrolled
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Phase 1 Completed
9 enrolled 7 charts
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Phase 1 Completed
13 enrolled 11 charts
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
Phase 1 Completed
12 enrolled 13 charts
DUET-4
Phase 1 Completed
78 enrolled
DUET-2
Phase 1 Completed
150 enrolled
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 Completed
28 enrolled 16 charts
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
Phase 1 Completed
26 enrolled
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Phase 1 Completed
35 enrolled
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Phase 1 Completed
18 enrolled
Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission
Phase 1 Completed
15 enrolled
ProGem2
Phase 1 Completed
25 enrolled
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
Phase 1 Completed
11 enrolled
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
Phase 1 Completed
10 enrolled
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
Phase 1 Completed
3 enrolled 11 charts
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Phase 1 Completed
36 enrolled
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer
Phase 1 Completed
44 enrolled
Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Phase 1 Completed
17 enrolled
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Phase 1 Completed
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 1 Completed
7 enrolled
Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
Phase 1 Completed
25 enrolled
Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase 1 Completed
30 enrolled
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
Phase 1 Completed
77 enrolled
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Phase 1 Completed
169 enrolled
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Phase 1 Completed
113 enrolled
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
Phase 1 Completed
40 enrolled
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase 1 Completed
41 enrolled
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
Phase 1 Completed
21 enrolled
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
Phase 1 Completed
11 enrolled
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 1 Completed
16 enrolled
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
Phase 1 Completed
23 enrolled
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 Completed
31 enrolled
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Phase 1 Completed
24 enrolled
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
Phase 1 Completed
98 enrolled